Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma

News   Nov 04, 2013

 
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
 
 
 
 

RELATED ARTICLES

Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?

News

A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.

READ MORE

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

News

TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.

READ MORE

A Rogue Gene is Causing Seizures in Babies. Here’s How MSU Wants to Stop it

News

The researchers are closer to understanding the source of the seizures, a gene known as GNAO1 and the transformations it can take on, and potentially stopping its devastating effects by uncovering key differences in the way it functions.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE